NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free ARCT Stock Alerts $27.93 +0.87 (+3.22%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$27.03▼$28.8050-Day Range$25.98▼$42.9952-Week Range$17.52▼$43.81Volume314,074 shsAverage Volume507,772 shsMarket Capitalization$751.88 millionP/E RatioN/ADividend YieldN/APrice Target$61.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside119.6% Upside$61.33 Price TargetShort InterestBearish19.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 4 Articles This WeekInsider TradingSelling Shares$910,434 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.83) to $2.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.93 out of 5 starsMedical Sector580th out of 909 stocksPharmaceutical Preparations Industry261st out of 425 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.60% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 14.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 2.5 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 11 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,434.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($2.83) to $2.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -26.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -26.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesMarch 28, 2024 | insidertrades.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in StockApril 23, 2024 | seekingalpha.comArcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic FibrosisApril 24, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 19, 2024 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Buy" from BrokeragesApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)April 9, 2024 | markets.businessinsider.comAlnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic PartnershipsApril 6, 2024 | cnn.comArcturus Therapeutics Holdings, Inc.April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline ProgressApril 24, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 29, 2024 | finanznachrichten.deIntravacc B.V.: Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine DevelopmentMarch 28, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) Insider Sells SharesMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in JapanMarch 22, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...March 17, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 16, 2024 | ca.finance.yahoo.comARCT Apr 2024 30.000 callMarch 11, 2024 | markets.businessinsider.comThe Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 ExpertsMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Xeris Pharmaceuticals (XERS) and Arcturus Therapeutics (ARCT)March 9, 2024 | seekingalpha.comArcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cigna (CI) and Arcturus Therapeutics (ARCT)March 8, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Arcturus Therapeutics Holdings Inc Earnings CallMarch 8, 2024 | finance.yahoo.comArcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline DevelopmentsMarch 7, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023March 7, 2024 | benzinga.comRecap: Arcturus Therapeutics Q4 EarningsMarch 7, 2024 | businesswire.comArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline ProgressMarch 7, 2024 | finance.yahoo.comARCT Sep 2024 30.000 putMarch 6, 2024 | benzinga.comEarnings Preview: Arcturus TherapeuticsSee More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$61.33 High Stock Price Target$90.00 Low Stock Price Target$45.00 Potential Upside/Downside+119.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-15.65% Pretax Margin-16.72% Return on Equity-18.22% Return on Assets-11.95% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual Sales$169.93 million Price / Sales4.42 Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book2.68Miscellaneous Outstanding Shares26,920,000Free Float23,201,000Market Cap$751.88 million OptionableOptionable Beta2.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsPliant TherapeuticsNASDAQ:PLRXOcular TherapeutixNASDAQ:OCULAurinia PharmaceuticalsNASDAQ:AUPHLongboard PharmaceuticalsNASDAQ:LBPHALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 55,237 shares on 4/24/2024Ownership: 0.205%Sumitomo Mitsui Trust Holdings Inc.Sold 44,133 shares on 4/19/2024Ownership: 4.742%Denali Advisors LLCBought 6,200 shares on 4/19/2024Ownership: 0.023%Allspring Global Investments Holdings LLCSold 85,253 shares on 4/18/2024Ownership: 0.110%Hennion & Walsh Asset Management Inc.Bought 778 shares on 4/17/2024Ownership: 0.119%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price target for 2024? 7 Wall Street research analysts have issued 12-month target prices for Arcturus Therapeutics' stock. Their ARCT share price targets range from $45.00 to $90.00. On average, they expect the company's share price to reach $61.33 in the next year. This suggests a possible upside of 119.6% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2024? Arcturus Therapeutics' stock was trading at $31.53 at the start of the year. Since then, ARCT shares have decreased by 11.4% and is now trading at $27.93. View the best growth stocks for 2024 here. Are investors shorting Arcturus Therapeutics? Arcturus Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the March 15th total of 4,210,000 shares. Based on an average daily trading volume, of 454,500 shares, the days-to-cover ratio is currently 10.6 days. Approximately 19.6% of the company's shares are sold short. View Arcturus Therapeutics' Short Interest. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.69) by $1.37. The biotechnology company had revenue of $33.99 million for the quarter, compared to analysts' expectations of $64.14 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 18.22% and a negative net margin of 15.65%. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), Amplify Treatments, Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA), AXS Green Alpha ETF (NXTE), Jacob Forward ETF (JFWD) and iShares Genomics Immunology and Healthcare ETF (IDNA). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.74%), Assenagon Asset Management S.A. (0.21%), Hennion & Walsh Asset Management Inc. (0.12%), Allspring Global Investments Holdings LLC (0.11%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARCT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
